Beam Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2023 Annual Meeting of Stockholders held by Beam Therapeutics Inc. on June 6, 2023. The filing details the voting outcomes for director elections, auditor ratification, and executive compensation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The following proposals were voted upon at the Annual Meeting:
- Proposal 1 (Director Elections): All Class III director nominees were elected to serve until the 2026 annual meeting.
- John Evans: 48,704,446 For; 250,291 Against; 124,211 Abstentions.
- John Maraganore, Ph.D.: 41,623,856 For; 7,441,072 Against; 14,020 Abstentions.
- Proposal 2 (Auditor Ratification): The appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023, was ratified.
- Votes: 60,120,184 For; 31,889 Against; 229,913 Abstentions.
- Proposal 3 (Executive Compensation): The compensation of named executive officers was approved on an advisory basis.
- Votes: 47,040,443 For; 1,996,717 Against; 41,788 Abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- John Maraganore, Ph.D. received a significantly higher number of "Against" votes (7.4 million) compared to John Evans (250k), representing approximately 15% of the votes cast for that nominee.
- Broker non-votes totaled 11,303,038 for the director election and executive compensation proposals.
- Deloitte & Touche LLP was overwhelmingly ratified as the independent auditor.
- Executive compensation received strong support with over 96% of votes cast in favor.